The Friedreich's Ataxia Research Alliance Announces That the FDA has Granted Orphan Drug Status for Research of Untreatable Rare Disease, Friedreich's Ataxia

The Friedreich's Ataxia Research Alliance Announces That the FDA has Granted Orphan Drug Status for Research of Untreatable Rare Disease, Friedreich's Ataxia

"This is an important step forward in moving EPI-743 towards approval for the treatment of Friedreich's ataxia."

Downingtown, PA (PRWEB) February 04, 2014: Edison Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia




FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia.

MOUNTAIN VIEW, Calif., Feb. 4, 2014 /PRNewswire/